Precigen
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Their mission is to discover, develop, and commercialize innovative therapies, with a vision to develop life-saving and cost-effective treatments for patients with unmet medical needs. The company operates as an innovation engine progressing a pipeline of therapies toward clinical proof-of-concept and commercialization.
Industries
Nr. of Employees
medium (51-250)
Precigen
20358 Seneca Meadows Parkway, Germantown, MD 20876
Patents
Products
Adenoviral vector-based investigational immunotherapies for HPV-associated cancers and recurrent respiratory papillomatosis
Investigational adenoviral vector immunotherapies designed to deliver optimized antigens or therapeutic genes to induce antigen-specific immune responses for HPV-associated cancers and HPV-mediated recurrent respiratory papillomatosis.
Autologous multigenic, non-viral CAR-T investigational therapies with rapid manufacturing
Autologous CAR-T therapies engineered via non-viral gene delivery to express multiple functional genes (CAR, localized cytokine, safety switch) and manufactured using rapid, same-day workflows for infusion the following day.
Adenoviral vector-based investigational immunotherapies for HPV-associated cancers and recurrent respiratory papillomatosis
Investigational adenoviral vector immunotherapies designed to deliver optimized antigens or therapeutic genes to induce antigen-specific immune responses for HPV-associated cancers and HPV-mediated recurrent respiratory papillomatosis.
Autologous multigenic, non-viral CAR-T investigational therapies with rapid manufacturing
Autologous CAR-T therapies engineered via non-viral gene delivery to express multiple functional genes (CAR, localized cytokine, safety switch) and manufactured using rapid, same-day workflows for infusion the following day.
Services
Policy and intake process to evaluate physician requests for pre-approval access to investigational therapeutics.
Collaborative research agreements and joint clinical development activities with academic and government research centers to advance investigational therapies into clinical trials.
Provision and deployment of rapid, decentralized manufacturing workflows and electroporation-based processing solutions to enable same-day autologous cell therapy production and infusion.
Policy and intake process to evaluate physician requests for pre-approval access to investigational therapeutics.
Collaborative research agreements and joint clinical development activities with academic and government research centers to advance investigational therapies into clinical trials.
Provision and deployment of rapid, decentralized manufacturing workflows and electroporation-based processing solutions to enable same-day autologous cell therapy production and infusion.
Expertise Areas
- Gene and cell therapy development
- CAR-T therapy engineering and manufacturing
- Viral vector vaccine and gene delivery
- Non-viral transposon-based cell engineering
Key Technologies
- Adenoviral vector delivery with large payload capacity
- Non-viral transposon/transposase systems for stable gene transfer
- Electroporation-based cell transfection (semi-closed, high-throughput)
- Membrane-bound cytokine engineering to augment T cells
News & Updates
Presenting promising data on two clinical programs in solid tumor indications, including Phase 1/1b study of PRGN-3005 in ovarian cancer and Phase I evaluation of PRGN-2009 in HPV-associated cancers.
The FDA has granted priority review to Precigen’s BLA for PRGN-2012, supporting its potential as a treatment for recurrent respiratory papillomatosis.
Presenting promising data on two clinical programs in solid tumor indications, including Phase 1/1b study of PRGN-3005 in ovarian cancer and Phase I evaluation of PRGN-2009 in HPV-associated cancers.
The FDA has granted priority review to Precigen’s BLA for PRGN-2012, supporting its potential as a treatment for recurrent respiratory papillomatosis.